Analysis of whole‐mammary gland carmine staining revealed no difference in the area covered by hyperplastic lesions in recIL‐22‐supplemented IL‐22+/+/PyMT mice compared to control IL‐22+/+/PyMT mice (P > 0.05; Fig. 3A,B) in both the hyperplasia and adenoma/MIN stages. The gene discussed is IL22; the disease is adenoma.